Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109278
Status:
COMPLETED
Last Update Posted:
2017-03-15
First Post:
2005-04-26
Brief Title:
A Measles Mumps and Rubella Investigational Vaccine Trial V205C-010COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Comparison of the Safety Tolerability and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin rHA Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin HSA in Healthy Children 12 to 18 Months of Age
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the safety of a measles mumps and rubella study vaccine made from a new measles stock seed a component of the vaccine made in 2003 with rHA recombinant human albumin
Detailed Description:
The duration of treatment is 6 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_016 | None | None | None |